Emory Transplant Center Active Clinical Trials

The Emory Transplant Center Clinical Research Program provides support for clinical trials encompassing end-organ diseases and solid organ transplantation for the Kidney, Kidney/Pancreas, Liver, Lung, Islet and Vascularized Composite Allograft programs. It is the goal of the ETC Clinical Research Program to maintain an active and diverse research portfolio that benefits our patients by providing opportunities to participate in cutting edge research initiatives, to advance the field of transplantation and to allow our investigators to contribute to scientific discovery.

Overall, our group supports 34 studies with 8 new projects in development. The program currently offers:

• 18 actively enrolling trials

• Includes 9 interventional trials

Kidney Transplantation

“Optimization of Belatacept Usage as a Means of Avoiding CNI and steroids in Renal Transplantation” (CTOT-10)
Principal Investigator: Ken Newell, MD

“Use of Belatacept during Post Depletional Repopulation to Facilitate Tolerance in Renal Allograft Recipients”(BMS IM 103-036)
Principal Investigator: Allan D. Kirk, MD, PhD

“Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation”
Principal Investigator: Paul Tso, MD

“An Observational Study to Assess the Prevalence of a Tolerance Signature in Renal Transplant Recipients” (ITN524st/CTOT-12)
Principal Investigator: Ken Newell, MD

Liver Transplantation

“HB-009: Evaluation of HepaGam B® in Combination with Antiviral Treatment in Hepatitis B Liver Transplant Patients”
Principal Investigator: Samir Parekh, MD

“Open-Label, Single Arm Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Black-African Americans, Latinos, and White-Caucasians with Chronic Hepatitis C Genotype 1 Infection”
Principal Investigator: James Spivey, MD

“A Randomized Trial of Telaprevir, Peginterferon, and Ribavirin versus Peginterferon and Ribavirin for Treatment of Genotype 1 Hepatitis C Virus with Host Interleukin 28B CC Polymorphism”
Principal Investigator: Ryan Ford, MD

“A Multi-center, Randmized, placebo-controlled, double-blind study to confirm the Reversal of Hepatorenal Syndrome Type-I with Leucassin (Terlipressin)” (REVERSE Trial)
Principal Investigator: Ram Subramanian, MD

“Treatment of Drug Overdose and Poisonings with the Molecular Adsorbent Recirculating System (MARS)”
Principal Investigator: Ram Subramanian, MD

Lung Transplantation

“A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected with Respiratory Syncytial Virus (RSV)”
Principal Investigator: David Neujahr, MD

Islet Transplantation

“Islet Transplantation versus Standard Medical Therapy in Type 1 Diabetic Kidney Allograft Recipients” (CIT-06)
Principal Investigator: Christian Larsen, MD, DPhil

“Islet Transplantation in Type 1 Diabetes with LEA29Y (Belatacept) Maintenance Therapy” (CIT-04)
Principal Investigator: Christian Larsen, MD, DPhil

“Islet Transplanation in Type 1 Diabetes” (CIT-07)
Principal Investigator: Christian Larsen, MD, DPhil

“Collaborative Islet Transplant Registry”
Principal Investigator: Nicole Turgeon, MD

Hand Transplantation

“Hand Transplantation for the Reconstruction of Below Elbow Amputations”
Principal Investigator: Linda Cendales, MD

If you are interested in learning more about these or other Emory Transplant Center Clinical Research projects, please call the ETC Clinical Research Program at 404-712-1114 to speak with one of our research coordinators.